Metadoksin

When ATH:
N07BB

Pharmacological action

Antialcoholic, hepatoprotective and detoxification agent, pyridoxine derivative (Vitamin B6). Accelerating the elimination of ethanol and acetaldehyde the body, activates enzymes, involved in the metabolism of ethanol. Restores the ratio of saturated and unsaturated free fatty acids in plasma, warns the primary structural degeneration of hepatocytes; inhibits the formation of collagen and fibronectin, It prevents the development of fibrosis and cirrhosis. It reduces craving for ethanol, It reduces the severity of psychic and somatic symptoms of hangover, reduces the relief of alcohol withdrawal syndrome. It normalizes the function of the liver detoxication, improves the mental state of patients, causing regression of depressive symptoms. It creates conditions for obtaining favorable results during the installation to change the psycho-alcoholic stereotype.

Pharmacokinetics

Absorption vыsokaya, bioavailability – 60-80%, plasma protein binding – 50%, T1/2 – 40-60 m. It is metabolized in the liver to active metabolites – pyridoxine and pyrrolidone carboxylate. Report the news – 45-50% during 24 no; through blood – 35-50% during 96 no.

Testimony

Acute alcohol intoxication, alcohol withdrawal syndrome, astenodepressivnyh state of psychotic nature.

In the combined therapy – liver diseases of various etiologies.

Dosage regimen

In acute alcohol intoxication – 600 mg / m or 600-900 mg / drip, during 1.5 no (breeding 500 ml 0.9% sodium or hloridal 5% dextrose), 1 time /

When alcohol withdrawal syndrome – 900 mg / drip, 1 time /, during 3-7 days, depending on the severity of the patient.

When alcoholic hepatopathy, during maintenance preventive treatment of chronic alcoholism – / m, by 500 mg, 3 The minimum duration of treatment – 90 days.

Liver and astenodepressivnyh state – inwards 500 mg 3, Duration of – no less 90

Side effect

Maybe: allergic reactions.

Contraindications

Pregnancy, lactation, Hypersensitivity to matedoksinu.

Cautions

C wary of patients, receiving antiparkinsonian drugs.

Drug Interactions

In an application reduces the effectiveness of levodopa.